Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Deadline for manuscript submissions: 31 May 2021
Print Special Issue Flyer (4)Eddie Fernando Candido Murta, MDE-MailWebsite
Department of Gynecology and Obstetrics/IPON (Research Institute of Oncology), Federal University of Triangulo Mineiro (UFTM), Uberaba, MG
Interests: Pathophysiology; Immunology and Immunotherapy (Dendritic Cell Vaccine) of Gynecological Cancer; Breast and Other Sites
Rosekeila Simõs Nomelini, MDE-MailWebsite
Department of Gynecology and Obstetrics/IPON (Research Institute of Oncology), Federal University of Triangulo Mineiro (UFTM), Uberaba, MG
Interests: Ovarian cancer; Uterine cervical cancer; Breast cancer; Cancer Immunology
Millena Prata Jammal, MDE-MailWebsite
Department of Gynecology and Obstetrics/IPON (Research Institute of Oncology), Federal University of Triangulo Mineiro (UFTM), Uberaba, MG
Interests: Ovarian cancer
Agrimaldo Martins Filho, MDE-MailWebsite
Research Institute of Oncology (IPON)/Department of Gynecology and Obstetrics, Federal University of Triangulo Mineiro, Uberaba, Brazil
Interests: Ovarian cancer
Cid Almeida de Lima, MDE-MailWebsite
Research Institute of Oncology (IPON)/Department of Gynecology and Obstetrics, Federal University of Triangulo Mineiro, Uberaba, Brazil
Interests: Ovarian cancer; Gynecologic cancer
Dear Colleagues,
The development of cancer may indicate a failure in the immune response through tumor escape mechanisms. The possibility of intervening and intensifying the action of the immune system to produce a beneficial anti-tumor response remains an area of intense research. Tumor cells exhibit a variety of escape mechanisms from immunodetection, leading to an ineffective immune response. In gynecological cancer, several cytokines and cells of the immune system can be used as potential markers, both for the diagnosis and for the prognosis of the disease. The profile of the immune response, whose differentiation and proliferation occurs in the production of certain cytokines, is capable of contributing to the induction of apoptosis, tumor control and regression. Several inflammatory mediators are induced by inflammatory and tumor cells and participate in the formation of cancer, acting as growth or angiogenic factors. One of the escape mechanisms that favors the maintenance of cancer is the triggering of an imbalance in the T helper 1 and T helper 2 response.
The tumor environment in which gynecological cancer develops has been described as a large site rich in pro-inflammatory cytokines and chemokines. Several of these cytokines are produced by the tumor itself, which in addition to stimulating the growth of tumor cells, are also responsible for creating a specific microenvironment that can promote cell proliferation and tumor growth, directly affecting the severity of inflammation.
Another important effector of the immune response to tumors is the peritumoral stroma. This stroma is composed of non-malignant tumor cells, such as cancer-associated fibroblast, mesenchymal cells, innate and adaptive immune cells, vasculature with endothelial cells and pericytes, in addition to an extracellular matrix consisting of structural proteins (collagen and elastin), specialized proteins (fibrillin, fibronectin and elastin) and proteoglycans.
Thus, the immune system plays a complex role in gynecological cancer and can, in different contexts, promote or inhibit tumor growth. The action of the immune system can be different in each gynecological tumor environment: systemic (study of the immune response in the serum of women with cancer), local (study of the tumor microenvironment and peritumoral stroma) and also in the sites around tumors (study of the response immune in the peritoneal fluid). The study of immunology in gynecological cancer is rich and may lead to the discovery of new diagnostic and prognostic markers. Consequently, new therapeutic targets will emerge with these researches, and improve the survival of gynecological cancer in the future.
Prof. Dr. Eddie Fernando Candido Murta, Dr. Rosekeila Simõs Nomelini, Dr. Agrimaldo Martins Filho and Dr. Cid Almeida de Lima
Guest Editors
Gynecological cancer;Immunology;Tumor microenvironment;Cytokines;Peritumoral stroma;Immune response
Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.
Immune response in cervical intraepithelial neoplasms
DOI: 10.31083/j.ejgo4205146
(This article belongs to the Special Issue Immunology in Gynecological Cancer)
Association of cancer-associated fibroblasts and survival in malignant ovarian neoplasms
DOI: 10.31083/j.ejgo4204118
(This article belongs to the Special Issue Immunology in Gynecological Cancer)
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.